Cargando…

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis

Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administ...

Descripción completa

Detalles Bibliográficos
Autor principal:	Min, Yong-Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384669/ https://www.ncbi.nlm.nih.gov/pubmed/25827453 http://dx.doi.org/10.3803/EnM.2015.30.1.19

Ejemplares similares

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
por: Cairoli, Elisa, et al.
Publicado: (2015)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
por: Słopień, Radosław, et al.
Publicado: (2017)

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
por: Nargesi, Shahin, et al.
Publicado: (2022)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
por: Sone, Teruki, et al.
Publicado: (2017)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis
por: Pitale, Shailesh, et al.
Publicado: (2015)

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS
por: Mirzaei, Alireza, et al.
Publicado: (2021)

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension
por: Koh, Jung-Min, et al.
Publicado: (2016)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2016)

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab
por: Scheiner, S, et al.
Publicado: (2014)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

A review of denosumab for the treatment of osteoporosis
por: Miyazaki, Tsuyoshi, et al.
Publicado: (2014)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
por: Papapoulos, S., et al.
Publicado: (2015)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Up-to-Date Knowledge on Osteoporosis Treatment Selection in Postmenopausal Women
por: Jeong, Hye Gyeong, et al.
Publicado: (2022)

Anabolic treatments for osteoporosis in postmenopausal women
por: Hassan, Neelam, et al.
Publicado: (2021)

Should denosumab treatment for osteoporosis be continued indefinitely?
por: Noble, Jane A., et al.
Publicado: (2021)

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
por: Silverman, Stuart L., et al.
Publicado: (2018)

Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
por: Lai, E. C.-C., et al.
Publicado: (2022)

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
por: Bone, Henry G., et al.
Publicado: (2013)

Does the VDR gene polymorphism influence the efficacy of denosumab therapy in postmenopausal osteoporosis?
por: Wawrzyniak, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pjkm3339f3bnf0kordjqfqse87